Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis
- 1 February 2002
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 46 (2), 228-241
- https://doi.org/10.1067/mjd.2002.120942
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitisJournal of the American Academy of Dermatology, 2001
- FK506 in the treatment of inflammatory skin disease: promises and perspectivesImmunology Today, 1996
- Pyoderma gangrenosum: Classification and managementJournal of the American Academy of Dermatology, 1996
- Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressantsJournal of Dermatological Science, 1994
- NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genesImmunology Today, 1994
- Inhibition of contact allergy reactions by topical FK506The Lancet, 1992
- The mechanism of action of cyclosporin A and FK506Immunology Today, 1992
- Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexesCell, 1991
- Molecular cloning and overexpression of the human FK506-binding protein FKBPNature, 1990
- Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin AScience, 1984